DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled CRSwNP.

THE ONLY BIOLOGIC APPROVED IN CHRONICRHINOSINUSITIS WITH NASAL POLYPOSIS

DUPIXENT is now approved for a new indication

DUPIXENT is the first and only dual inhibitor of IL-4 and IL-13 signaling approved in CRSwNP1

    Reference:
  1. DUPIXENT Prescribing Information. June 2019.